Amrutanjan Health Care Reports Robust Q2 Performance with 18.4% Profit Growth

Amrutanjan Health Care Limited has announced strong financial results for the second quarter, demonstrating significant growth across key metrics.

Financial Highlights

The company's performance for Q2 shows impressive year-over-year improvements:

Metric	Q2 FY2025-26	Q2 FY2024-25	YoY Change
Net Profit	₹139.60 crore	₹117.90 crore	+18.4%
Revenue	₹1,177.00 crore	₹1,099.10 crore	+7.1%
EBITDA	₹165.20 crore	₹136.00 crore	+21.5%
EBITDA Margin	14.04%	12.38%	+166 bps

Performance Analysis

Amrutanjan Health Care has demonstrated robust growth in the second quarter, with net profit rising by 18.4% year-over-year to ₹139.60 crore. This significant increase in profitability was accompanied by a 7.1% growth in revenue, which reached ₹1,177.00 crore for the quarter.

The company's operational efficiency has also shown marked improvement, as evidenced by the EBITDA growth of 21.5% to ₹165.20 crore. The EBITDA margin expanded by 166 basis points to 14.04%, indicating enhanced operational performance and cost management.

Corporate Actions

In addition to the quarterly results, Amrutanjan Health Care's Board of Directors has declared a first interim dividend of ₹1 per share. The company has set November 18, 2025, as the record date for dividend payment.

Outlook

The company's ability to grow its revenue while simultaneously expanding its profit margins suggests a positive trajectory for Amrutanjan Health Care. The improved EBITDA margin indicates that the company is effectively managing its costs while driving growth, which could bode well for future performance.

Investors and market observers will likely keep a close watch on Amrutanjan Health Care's performance in the coming quarters to see if this growth momentum can be sustained, especially in light of broader economic conditions and industry trends.

As always, stakeholders are advised to consider these results in the context of broader market conditions and to consult with financial advisors before making investment decisions.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.09%	-2.16%	-8.14%	-5.38%	-6.37%	+36.78%

Amrutanjan Health Care Limited , a prominent player in the healthcare sector, has announced impressive financial results for the quarter ended June 30, 2025, alongside key corporate updates.

Financial Highlights

The company reported a substantial 80% increase in profit after tax, reaching ₹831.12 lakhs for the quarter, compared to ₹461.56 lakhs in the same period last year. This significant growth was accompanied by a 12.3% rise in revenue from operations, which climbed to ₹9,404.57 lakhs from ₹8,373.60 lakhs year-on-year.

The financial performance for the quarter is summarized in the table below:

Particulars (in ₹ lakhs)	Q1 FY2026	Q1 FY2025	YoY Change
Revenue from Operations	9,404.57	8,373.60	+12.3%
Profit After Tax	831.12	461.56	+80.0%
Basic EPS (in ₹)	2.87	1.60	+79.4%

The company's basic earnings per share (EPS) also saw a significant improvement, standing at ₹2.87 compared to ₹1.60 in the previous year's quarter.

Segment Performance

Amrutanjan Health Care's unaudited financial results reveal segment-wise performance:

OTC Products: Remained the largest contributor with revenue of ₹5,697.24 lakhs.
Women's Hygiene: Generated revenue of ₹2,860.75 lakhs.
Beverages: Contributed ₹776.01 lakhs to the total revenue.
Others (including Pain Management Centre): Recorded ₹70.57 lakhs in revenue.

Corporate Updates

The company's Board of Directors convened on August 12, 2025, and approved several key decisions:

Annual General Meeting: The 88th Annual General Meeting (AGM) is scheduled for September 23, 2025, to be held via video conference.
Record Date: September 16, 2025, has been set as the record date for determining shareholder eligibility for voting at the AGM and for final dividend payment.
Share Transfer Closure: The share transfer register will be closed from September 17 to September 23, 2025 (both days inclusive).
Secretarial Auditor Appointment: M/s. SPNP & Associates, Practicing Company Secretaries, have been appointed as the Secretarial Auditor for a five-year term starting April 1, 2025, subject to shareholder approval at the upcoming AGM.

Management Commentary

While specific management comments were not provided, the robust financial performance indicates strong execution of the company's business strategies and effective management of market conditions.

Amrutanjan Health Care Limited continues to demonstrate resilience and growth in the competitive healthcare sector. The significant increase in profitability and steady revenue growth reflect the company's strong market position and operational efficiency. Investors and stakeholders will be keenly watching the upcoming AGM for further insights into the company's future strategies and dividend announcements.